Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188419 · ClinicalTrials.gov registry record
Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 161
- Enrollment target
NCT03188419: Completed study, sponsored by National Cancer Institute (NCI).
NCT03188419 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03188419 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
Background: People who have certain immune system diseases often need a procedure called allo HSCT. This is short for allogeneic hematopoietic stem cell transplant. This might cure people with these diseases. Many people who need allo HSCT need donors who are relatives with similar genes. But the disease may also affect those in the donor pool. This may mean there are fewer options for people with inherited diseases. Researchers want to collect data on how transplant candidates and their donors are found. Objective: To find out how genetic diseases and the ways they are inherited affect the breadth of options for allo HSCT donors. Eligibility: Records from studies that have already been done. These will be for people ages 4 and older who were evaluated for allo HSCT or to be donors. Design: Participants already signed a consent form for their records to be shared. Researchers will study the participant data. Data will be stored in an electronic system. Researchers will use passwords to protect the data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2020-02-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03188419
The ClinicalTrials.gov registry entry for NCT03188419 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03188419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03188419 about?
NCT03188419 is a clinical study titled "Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide". Background: People who have certain immune system diseases often need a procedure called allo HSCT. This is short for allogeneic hematopoietic stem cell transplant. This might cure people with these diseases. Many people who need allo HSCT need donors who are relatives with similar genes. But the d...
What is the current status of trial NCT03188419?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2017-06-14. Estimated completion is 2020-02-20.
Who is sponsoring clinical trial NCT03188419?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.